Cash flow Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 13/09/2024 pm IST			5-day change	1st Jan Change
1,800.00 ^DKK	+1.18%		-3.23%	-16.47%

09/09	Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	MT
04/09	Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM

42abed86a0b4b2c5ebec018.dmO0km0chQWSvJZZJS1yNq1RDY3FLEi5pTv1uFEzP_Q.FQmFxCNVvGrb1t5qHGkXVfsBZL2caAPS7wO07iZUXJUBV9zxJVnhUfXa-Q

Published financial data: GENMAB A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	536.6Cr	1.01TCr	848.2Cr	1.46TCr	1.65TCr
Total Revenues	536.6Cr	1.01TCr	848.2Cr	1.46TCr	1.65TCr
Cost of Goods Sold, Total	-	-	-	-	23Cr
Gross Profit	536.6Cr	1.01TCr	848.2Cr	1.46TCr	1.62TCr
Selling General & Admin Expenses, Total	34Cr	66Cr	128.3Cr	267.6Cr	329.7Cr
R&D Expenses	238.6Cr	311.5Cr	418.1Cr	552.4Cr	763Cr
Other Operating Expenses, Total	272.8Cr	377.6Cr	546.4Cr	820Cr	1.09TCr
Operating Income	263.8Cr	633.5Cr	301.8Cr	639.5Cr	532.1Cr
Interest Expense, Total	-70L	-1Cr	-1.3Cr	-2.1Cr	-2.7Cr
Interest And Investment Income	12Cr	18Cr	20Cr	32Cr	94Cr
Net Interest Expenses	11Cr	17Cr	18Cr	30Cr	91Cr
Currency Exchange Gains (Loss)	9.9Cr	-145.6Cr	147Cr	103.4Cr	-89Cr
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	285Cr	505.3Cr	467.2Cr	773.2Cr	534.4Cr
Gain (Loss) On Sale Of Investments	90L	87Cr	-69Cr	-66Cr	29Cr
Asset Writedown	-	-2.2Cr	-	-3.8Cr	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	285.9Cr	590.4Cr	398.3Cr	703.5Cr	563.7Cr
Income Tax Expense	69Cr	114.6Cr	98Cr	151.3Cr	128.5Cr
Earnings From Continuing Operations	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Net Income to Company	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Net Income - (IS)	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Net Income to Common Incl Extra Items	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Net Income to Common Excl. Extra Items	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Per Share Items
Net EPS - Basic	34.4	73	46	84.45	66.64
Basic EPS - Continuing Operations	34.4	73	46	84.45	66.64
Basic Weighted Average Shares Outstanding	6.3Cr	6.52Cr	6.54Cr	6.54Cr	6.53Cr
Net EPS - Diluted	34.03	72.21	45.54	83.65	66.02
Diluted EPS - Continuing Operations	34.03	72.21	45.54	83.65	66.02
Diluted Weighted Average Shares Outstanding	6.36Cr	6.59Cr	6.6Cr	6.6Cr	6.59Cr
Normalized Basic EPS	28.29	48.45	44.65	73.91	51.14
Normalized Diluted EPS	27.99	47.93	44.21	73.21	50.67
American Depositary Receipts Ratio (ADR)	0.1	0.1	0.1	0.1	0.1
Supplemental Items
EBITDA	277.7Cr	656.5Cr	326.6Cr	671.9Cr	556.1Cr
EBITA	273.7Cr	644.4Cr	310.2Cr	646.5Cr	537.6Cr
EBIT	263.8Cr	633.5Cr	301.8Cr	639.5Cr	532.1Cr
EBITDAR	278.3Cr	656.8Cr	326.7Cr	-	-
Effective Tax Rate - (Ratio)	24.24	19.41	24.48	21.51	22.8
Current Domestic Taxes	44Cr	119.1Cr	97Cr	149.8Cr	-
Total Current Taxes	44Cr	119.1Cr	97Cr	149.8Cr	130.1Cr
Deferred Domestic Taxes	25Cr	-4.5Cr	70L	1.5Cr	-
Total Deferred Taxes	25Cr	-4.5Cr	70L	1.5Cr	-1.6Cr
Normalized Net Income	178.12Cr	315.81Cr	292Cr	483.25Cr	334Cr
Interest on Long-Term Debt	70L	1Cr	1.3Cr	2.1Cr	2.7Cr
Supplemental Operating Expense Items
General and Administrative Expenses	34Cr	66Cr	-	-	-
Research And Development Expense From Footnotes	238.6Cr	313.7Cr	418.1Cr	556.2Cr	763Cr
Net Rental Expense, Total	60L	30L	10L	-	-
Imputed Operating Lease Interest Expense	-	10L	3L	-	-
Imputed Operating Lease Depreciation	-	20.4L	7L	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., Other (Total)	15Cr	20Cr	31Cr	44Cr	59Cr
Total Stock-Based Compensation	15Cr	20Cr	31Cr	44Cr	59Cr

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	355.2Cr	726Cr	895.7Cr	989.3Cr	1.49TCr
Short Term Investments	741.9Cr	881.9Cr	1.04TCr	1.24TCr	1.33TCr
Total Cash And Short Term Investments	1.1TCr	1.61TCr	1.93TCr	2.23TCr	2.81TCr
Accounts Receivable, Total	299Cr	246.3Cr	336.7Cr	591Cr	494.7Cr
Other Receivables	-	25Cr	3.1Cr	14Cr	-
Total Receivables	299Cr	271.2Cr	339.8Cr	605.3Cr	494.7Cr
Inventory	-	-	-	-	5.7Cr
Total Current Assets	1.4TCr	1.88TCr	2.27TCr	2.84TCr	3.31TCr
Gross Property Plant And Equipment	63Cr	100Cr	134.3Cr	181.7Cr	231.7Cr
Accumulated Depreciation	-22Cr	-26Cr	-37Cr	-50Cr	-68Cr
Net Property Plant And Equipment	41Cr	74Cr	98Cr	132.2Cr	164.1Cr
Long-term Investments	15Cr	108.1Cr	37Cr	13Cr	13Cr
Other Intangibles, Total	47Cr	34Cr	25Cr	15Cr	10Cr
Accounts Receivable Long-Term	1.1Cr	2Cr	2.7Cr	4.8Cr	6.2Cr
Deferred Tax Assets Long-Term	14Cr	18Cr	26Cr	25Cr	21Cr
Total Assets	1.51TCr	2.11TCr	2.46TCr	3.03TCr	3.53TCr
Liabilities
Accounts Payable, Total	-	-	35Cr	-	-
Accrued Expenses, Total	-	-	30Cr	-	-
Current Portion of Leases	2.6Cr	4.2Cr	6.2Cr	7.4Cr	9Cr
Current Income Taxes Payable	7.3Cr	-	-	-	5.4Cr
Unearned Revenue Current, Total	-	2.6Cr	2.6Cr	3.3Cr	3.3Cr
Other Current Liabilities	84Cr	118.5Cr	83Cr	171.6Cr	230.7Cr
Total Current Liabilities	94Cr	125.3Cr	156.8Cr	182.3Cr	248.4Cr
Long-Term Leases	16Cr	28Cr	36Cr	52Cr	68Cr
Unearned Revenue Non Current	-	49Cr	49Cr	48Cr	48Cr
Other Non Current Liabilities	30L	50L	1.3Cr	1.1Cr	3.5Cr
Total Liabilities	109.6Cr	202.2Cr	243.1Cr	283.7Cr	367.9Cr
Common Stock, Total	6.5Cr	6.6Cr	6.6Cr	6.6Cr	6.6Cr
Additional Paid In Capital	1.18TCr	1.19TCr	1.2TCr	1.23TCr	1.25TCr
Retained Earnings	213Cr	710.7Cr	1TCr	1.5TCr	1.9TCr
Comprehensive Income and Other	9.8Cr	5.4Cr	8.1Cr	9.8Cr	6Cr
Total Common Equity	1.4TCr	1.91TCr	2.22TCr	2.74TCr	3.16TCr
Total Equity	1.4TCr	1.91TCr	2.22TCr	2.74TCr	3.16TCr
Total Liabilities And Equity	1.51TCr	2.11TCr	2.46TCr	3.03TCr	3.53TCr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	6.49Cr	6.54Cr	6.54Cr	6.54Cr	6.53Cr
ECS Total Common Shares Outstanding	6.49Cr	6.54Cr	6.54Cr	6.54Cr	6.53Cr
Book Value / Share	216.42	292.31	339.23	419.77	483.85
Tangible Book Value	1.36TCr	1.88TCr	2.19TCr	2.73TCr	3.15TCr
Tangible Book Value Per Share	209.18	287.14	335.35	417.54	482.3
Total Debt	18Cr	32Cr	42Cr	60Cr	77Cr
Net Debt	-1.08TCr	-1.58TCr	-1.89TCr	-2.17TCr	-2.74TCr
Debt Equivalent Oper. Leases	4.8Cr	2.4Cr	80L	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	-	-	-	-	1.4Cr
Inventories - Finished Goods, Total	-	-	-	-	5.9Cr
Machinery, Total	28Cr	42Cr	54Cr	65Cr	91Cr
Full Time Employees	548	781	1.21T	1.66T	2.2T

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	216.6Cr	475.8Cr	300.8Cr	552.2Cr	435.2Cr
Depreciation & Amortization - CF	8.8Cr	16Cr	22Cr	33Cr	18Cr
Amortization of Goodwill and Intangible Assets - (CF)	9.9Cr	11Cr	8.4Cr	7Cr	5.5Cr
Depreciation & Amortization, Total	19Cr	27Cr	30Cr	40Cr	24Cr
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-90L	-87Cr	69Cr	66Cr	-29Cr
Asset Writedown & Restructuring Costs	-	2.9Cr	-	3.8Cr	-
Stock-Based Compensation (CF)	15Cr	20Cr	31Cr	44Cr	59Cr
Other Operating Activities, Total	5.3Cr	106.6Cr	-131.3Cr	-121.4Cr	113.3Cr
Change In Accounts Receivable	-165.8Cr	31Cr	-107.4Cr	-221.3Cr	80Cr
Change In Inventories	-	-	-	-	-5.7Cr
Change In Accounts Payable	44Cr	17Cr	30Cr	28Cr	62Cr
Change in Unearned Revenues	-	51Cr	-	-	-
Change in Other Net Operating Assets	-	-	-	-	-
Cash from Operations	132.6Cr	643.3Cr	222.8Cr	391.2Cr	738Cr
Capital Expenditure	-7.9Cr	-31Cr	-25Cr	-32Cr	-37Cr
Sale of Property, Plant, and Equipment	-	-	-	-	-
Sale (Purchase) of Intangible assets	-3.2Cr	-	-	-	-1Cr
Investment in Marketable and Equity Securities, Total	-187.2Cr	-204.4Cr	-71Cr	-244.4Cr	-91Cr
Cash from Investing	-198.3Cr	-235.1Cr	-96Cr	-276.1Cr	-128.2Cr
Long-Term Debt Repaid, Total	-3.1Cr	-4.4Cr	-5.8Cr	-7.3Cr	-9.1Cr
Total Debt Repaid	-3.1Cr	-4.4Cr	-5.8Cr	-7.3Cr	-9.1Cr
Issuance of Common Stock	393.8Cr	14Cr	14Cr	28Cr	15Cr
Repurchase of Common Stock	-90L	-2.5Cr	-50Cr	-100Cr	-67Cr
Other Financing Activities, Total	-24Cr	-	-	-	-
Cash from Financing	366Cr	7.1Cr	-42Cr	-79Cr	-61Cr
Foreign Exchange Rate Adjustments	1.6Cr	-44Cr	85Cr	57Cr	-52Cr
Net Change in Cash	301.9Cr	370.8Cr	169.7Cr	94Cr	497.4Cr
Supplemental Items
Cash Interest Paid	2Cr	2Cr	1.2Cr	1.6Cr	2.5Cr
Cash Income Tax Paid (Refund)	48Cr	147.6Cr	74Cr	158.3Cr	106.7Cr
Levered Free Cash Flow	67Cr	468.91Cr	184.91Cr	209.18Cr	529.38Cr
Unlevered Free Cash Flow	68Cr	469.54Cr	185.72Cr	210.49Cr	531.06Cr
Change In Net Working Capital	119.5Cr	-58Cr	39Cr	241.2Cr	-153.5Cr
Net Debt Issued / Repaid	-3.1Cr	-4.4Cr	-5.8Cr	-7.3Cr	-9.1Cr

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	13.97	21.82	8.24	14.56	10.17
Return on Total Capital	14.82	23.52	8.97	15.78	11.04
Return On Equity %	19.64	28.69	14.56	22.25	14.78
Return on Common Equity	19.64	28.69	14.56	22.25	14.78
Margin Analysis
Gross Profit Margin %	100	100	100	100	98.63
SG&A Margin	6.37	6.54	15.13	18.34	20.01
EBITDA Margin %	51.75	64.93	38.5	46.04	33.76
EBITA Margin %	51.01	63.73	36.57	44.3	32.63
EBIT Margin %	49.16	62.65	35.58	43.82	32.3
Income From Continuing Operations Margin %	40.37	47.06	35.46	37.83	26.42
Net Income Margin %	40.37	47.06	35.46	37.83	26.42
Net Avail. For Common Margin %	40.37	47.06	35.46	37.83	26.42
Normalized Net Income Margin	33.2	31.23	34.43	33.11	20.27
Levered Free Cash Flow Margin	12.53	46.38	21.8	14.33	32.13
Unlevered Free Cash Flow Margin	12.61	46.44	21.9	14.42	32.24
Asset Turnover
Asset Turnover	0.45	0.56	0.37	0.53	0.5
Fixed Assets Turnover	18.63	17.58	9.91	12.71	11.12
Receivables Turnover (Average Receivables)	2.49	3.71	2.91	3.15	3.09
Short Term Liquidity
Current Ratio	14.88	15	14.5	15.57	13.34
Quick Ratio	14.88	15	14.5	15.57	13.32
Operating Cash Flow to Current Liabilities	1.41	5.13	1.42	2.15	2.97
Days Sales Outstanding (Average Receivables)	146.82	98.69	125.44	116	118.08
Long Term Solvency
Total Debt/Equity	1.29	1.67	1.91	2.18	2.44
Total Debt / Total Capital	1.27	1.64	1.88	2.13	2.38
LT Debt/Equity	1.1	1.45	1.64	1.91	2.15
Long-Term Debt / Total Capital	1.09	1.42	1.6	1.87	2.1
Total Liabilities / Total Assets	7.24	9.56	9.87	9.37	10.43
EBIT / Interest Expense	376.86	633.5	232.15	304.52	197.07
EBITDA / Interest Expense	403.57	660.1	255.54	323.48	205.96
(EBITDA - Capex) / Interest Expense	392.29	629.4	236.15	308.38	192.41
Total Debt / EBITDA	0.06	0.05	0.13	0.09	0.14
Net Debt / EBITDA	-3.82	-2.39	-5.69	-3.2	-4.92
Total Debt / (EBITDA - Capex)	0.07	0.05	0.14	0.09	0.15
Net Debt / (EBITDA - Capex)	-3.93	-2.5	-6.16	-3.36	-5.27
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	77.39	88.43	-16.11	72.07	13.57
Gross Profit, 1 Yr. Growth %	77.39	88.43	-16.11	72.07	12.02
EBITDA, 1 Yr. Growth %	89.17	136.41	-50.25	105.73	-14.72
EBITA, 1 Yr. Growth %	90.07	135.44	-51.86	108.41	-15.67
EBIT, 1 Yr. Growth %	91.16	140.14	-52.36	111.9	-15.61
Earnings From Cont. Operations, 1 Yr. Growth %	47.15	119.67	-36.78	83.58	-20.18
Net Income, 1 Yr. Growth %	47.15	119.67	-36.78	83.58	-20.18
Normalized Net Income, 1 Yr. Growth %	75.6	77.3	-7.54	65.5	-30.07
Diluted EPS Before Extra, 1 Yr. Growth %	43.4	112.2	-36.93	83.68	-20.06
Accounts Receivable, 1 Yr. Growth %	125.32	-17.63	36.7	75.53	-13.39
Net Property, Plant and Equip., 1 Yr. Growth %	155.56	77.78	32.47	35.59	24.13
Total Assets, 1 Yr. Growth %	78.99	39.61	16.48	22.95	17.17
Tangible Book Value, 1 Yr. Growth %	79.98	38.33	16.82	24.4	16.12
Common Equity, 1 Yr. Growth %	75.29	36.11	16.08	23.63	15.86
Cash From Operations, 1 Yr. Growth %